|
|
Module
|
In this CME-certified module, review key insights into the latest clinical developments and emerging therapeutic approaches for GVHD, presented by faculty experts Nelson Chao, MD, MBA, and David Miklos, MD, PhD.
Learning Objectives
Upon completion of this activity, participants should be able to:
-
Describe current advances in our understanding of the biology of GVHD
-
Discuss the role of new pharmacologic interventions and how they can intersect with the pathogenesis of GVHD
-
Identify ongoing trials of investigational approaches in the prevention and treatment of GVHD to aid referral of patients for study participation
Topics covered include:
- Introduction
- GVHD: Background and Overview
- Emerging Therapeutic Targets in GVHD
- Managing Acute GVHD
- Managing Chronic GVHD
|
Faculty
-
|
|
Nelson Chao
MD, MBA
|
|
|
David Miklos
MD, PhD
|
Credit Information
|
Information on this Educational Activity
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|
Faculty
|
|
Nelson Chao, MD, MBA
Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematology Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, North Carolina
|
Nelson Chao, MD, MBA, has no real or apparent conflicts of interest to report.
|
| |
|
David Miklos, MD, PhD
Associate Professor of Medicine
Clinical Director, Cancer Cell Therapy Program
Division of Blood and Marrow Transplantation
Stanford University
Stanford, California
|
David Miklos, MD, PhD, has disclosed that he has received consulting fees from Kite Pharma, Novartis, and Pharmacyclics and funds for research support from Genentech, Kite Pharma, and Pharmacyclics.
|
| |
Staff
|
|
Megan Cartwright, PhD
Clinical Editor
|
Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
|
| |
|
Terrence Fagan,
Associate Managing Editor
|
Terrence Fagan has no real or apparent conflicts of interest to report.
|
| |
|
Timothy A. Quill, PhD
Senior Managing Editor
|
Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
|
| |
|
Kevin Obholz, PhD
Editorial Director, Hematology/Oncology
|
Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
|
| |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
| |
Target Audience
This program is intended for physicians and other healthcare providers who care for patients with or at risk of graft-vs-host disease.
Goal
The goal of this activity is to improve participants’ knowledge and competence in applying emerging targeted pharmacologic interventions to prevent or manage GVHD.
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current advances in our understanding of the biology of GVHD
- Discuss the role of new pharmacologic interventions and how they can intersect with the pathogenesis of GVHD
- Identify ongoing trials of investigational approaches in the prevention and treatment of GVHD to aid referral of patients for study participation
|
| |
Physician Continuing Medical Education
|
|
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
| |
Commercial Support |
This program is supported by an educational grant
from Incyte.
|
| |
Program Medium |
This program has been made available online.
|
| |
Site Requirements |
- Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
- JavaScript enabled
- 1024x768+ screen resolution
- Adobe Flash Player
|
| |
Instructions for Credit
Participation in this self-study activity should be completed in approximately 1 hour.
To successfully complete this activity and receive credit, participants must follow these steps during the period from
December 05, 2017, through December 04, 2018:
|
|
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate.
After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page.
Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
|
|
|